InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Sagimet Biosciences Inc.

SGMT Clue Score32
United States Fiscal year ends December CIK 0001400118
$8.93 +0.11% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $8.93 +12.75% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 14 Jul 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Operating income−31.1Net income−30.5EPS, diluted−165.20Fiscal year 2023Revenue2.0Operating income−30.7Net income−27.9EPS, diluted−2.66Fiscal year 2024Operating income−54.5Net income−45.6EPS, diluted−1.45Fiscal year 2025Operating income−56.9Net income−51.0EPS, diluted−1.58
FY2022FY2023FY2024FY2025
Revenue n/a 2.0 n/a n/a
Growth
Operating income −31.1 −30.7 −54.5 −56.9
Net income −30.5 −27.9 −45.6 −51.0
Growth
EPS, diluted −165.20 −2.66 −1.45 −1.58

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2022Fiscal year 2023Operating margin−1,537.0%Net margin−1,393.8%Fiscal year 2024Fiscal year 2025
FY2022FY2023FY2024FY2025
Operating margin n/a −1,537.0% n/a n/a
Net margin n/a −1,393.8% n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2022Operating cash flow−24.5Fiscal year 2023Operating cash flow−23.8Fiscal year 2024Operating cash flow−42.4Fiscal year 2025Operating cash flow−45.7
FY2022FY2023FY2024FY2025
Operating cash flow −24.5 −23.8 −42.4 −45.7

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash0.2Shareholders’ equity−187.0Fiscal year 2023Cash75.1Shareholders’ equity91.1Fiscal year 2024Cash75.8Shareholders’ equity155.8Fiscal year 2025Cash35.0Shareholders’ equity111.4
FY2022FY2023FY2024FY2025
Cash 0.2 75.1 75.8 35.0
Shareholders’ equity −187.0 91.1 155.8 111.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a 2.0 n/a n/a
Growth
24.9 19.8 38.4 39.1
6.1 13.0 16.0 17.8
−31.1 −30.7 −54.5 −56.9
Growth
n/a n/a 0.0 0.0
−30.5 −27.9 −45.6 −51.0
Growth
Per share
−165.20 −2.66 −1.45 −1.58
−165.20 −2.66 −1.45 −1.58
Growth
0.2 10.5 31.4 32.3
0.2 10.5 31.4 32.3
Growth +5,565.9% +199.7% +3.2%

† The diluted share count jumps at 2023 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 4 of 4 years on file.